Aberrant expression of E-cadherin and beta-catenin in human prostate cancer.
about
Androgen receptor footprint on the way to prostate cancer progressionBeta-catenin phosphorylated at threonine 120 antagonizes generation of active beta-catenin by spatial localization in trans-Golgi networkIn utero exposure to tributyltin alters the expression of E-cadherin and localization of claudin-1 in intercellular junctions of the rat ventral prostateE-cadherin and β-catenin adhesion proteins correlate positively with connexins in colorectal cancer.Curcumin attenuates β-catenin signaling in prostate cancer cells through activation of protein kinase D1.p21CIP-1/WAF-1 induction is required to inhibit prostate cancer growth elicited by deficient expression of the Wnt inhibitor Dickkopf-1.The role of adhesion molecules as biomarkers for the aggressive prostate cancer phenotype.Network-based prediction for sources of transcriptional dysregulation using latent pathway identification analysis.Mechanism of β-catenin-mediated transcriptional regulation of epidermal growth factor receptor expression in glycogen synthase kinase 3 β-inactivated prostate cancer cellsAssociation of molecular biomarkers expression with biochemical recurrence in prostate cancer through tissue microarray immunostaining.Stimulation of prostate cancer cellular proliferation and invasion by the androgen receptor co-activator ARA70Holding Tight: Cell Junctions and Cancer Spread.A prostatic intraepithelial neoplasia-dependent p27 Kip1 checkpoint induces senescence and inhibits cell proliferation and cancer progressionDysfunctional transforming growth factor-beta receptor II accelerates prostate tumorigenesis in the TRAMP mouse modelβ-catenin as a prognostic factor for prostate cancer (PCa).T-cadherin in prostate cancer: relationship with cancer progression, differentiation and drug resistanceSoy isoflavones and prostate cancer: a review of molecular mechanisms.Steps in prostate cancer progression that lead to bone metastasisEmerging roles of protein kinase D1 in cancer.Wnt signaling in castration-resistant prostate cancer: implications for therapy.The intercellular adhesion molecule, cadherin-10, is a marker for human prostate luminal epithelial cells that is not expressed in prostate cancer.E-cadherin expression increases cell proliferation by regulating energy metabolism through nuclear factor-κB in AGS cells.Restoration of PPP2CA expression reverses epithelial-to-mesenchymal transition and suppresses prostate tumour growth and metastasis in an orthotopic mouse model.Par-4 dependent modulation of cellular β-catenin by medicinal plant natural product derivative 3-azido Withaferin A.Peroxisome proliferator-activated receptor gamma regulates E-cadherin expression and inhibits growth and invasion of prostate cancerInduction of reactive oxygen species generation inhibits epithelial-mesenchymal transition and promotes growth arrest in prostate cancer cellsProtein kinase D signaling in cancer: A friend or foe?Inhibition of IGF-1 signaling by genistein: modulation of E-cadherin expression and downregulation of β-catenin signaling in hormone refractory PC-3 prostate cancer cells.Leupaxin acts as a mediator in prostate carcinoma progression through deregulation of p120catenin expression.Improvement in predicting tumorigenic phenotype of androgen-insensitive human LNCaP prostatic cancer cell subline in recombination with rat urogenital sinus mesenchyme.Cadherin switching and activation of beta-catenin signaling underlie proinvasive actions of calcitonin-calcitonin receptor axis in prostate cancer.The role of SRC family kinases in prostate cancer.Beta-catenin mediates alteration in cell proliferation, motility and invasion of prostate cancer cells by differential expression of E-cadherin and protein kinase D1.Primary cilia are lost in preinvasive and invasive prostate cancer.Optimization and comprehensive characterization of a faithful tissue culture model of the benign and malignant human prostate.miR-223 promotes colon cancer by directly targeting p120 catenin.Alterations in beta-catenin expression and localization in prostate cancer.Overexpression of E-cadherin and beta-catenin proteins in metastatic prostate cancer cells in bone.Differential immunohistochemical expression of CD44s, E-cadherin and β-catenin among hyperplastic and neoplastic lesions of the prostate gland.Markers of epithelial-to-mesenchymal transition reflect tumor biology according to patient age and Gleason score in prostate cancer.
P2860
Q26825402-AFE9A89B-E324-4608-B0EB-8A1BAB701684Q28482268-A1B82316-6C8D-4895-BC6F-A96BFAE94435Q28580259-341E3462-F366-4CD2-9FD2-4060C4EF4E87Q33727622-3B26AEE4-B169-42F2-838B-7151496CD14EQ34241833-2F51966C-F98F-45AA-B0BE-ADDB014A4EEEQ34685574-30A83C25-0CE3-4CF1-8ED4-EF876D234415Q35072541-880ED4BF-15EE-4F12-A525-BD23D47EC5A5Q35164684-5BF4393C-4E4C-4F89-9ED7-40D36C13754AQ36002945-1E170336-E276-45BA-A041-0C244421E922Q36085432-929F41B8-1330-4082-9886-9D4F51C897F4Q36357367-155CEFF0-F203-414E-B78A-D850171F303AQ36638980-CF4FBE99-E197-4D0C-98CD-3771BE1291C0Q36974094-885F6772-121B-41E5-AC41-FDAB8E2A8292Q37355355-B5B91566-65CB-47E7-9C9F-47DAFFEC1D5FQ37579140-57C63BAB-9E1C-4634-B9D4-98B6147D356FQ37601733-F4EF6AE4-ED4F-4A80-A831-6D0F1B5A9306Q37654590-1FCA0E4A-E6D6-4B16-9304-867842352EB3Q37848782-0C9D7B3E-6A50-4A26-B74F-08A444298237Q37890712-14C1E613-AFAA-4063-BF77-C4203EA67260Q38241850-26C3EA54-437C-4055-A54F-CD16B3991000Q38428634-BDCF8C1A-0D79-4053-9341-FD3121EEFEFFQ38697504-9A07E5A6-D91D-41BA-9A31-A371C138013EQ38838867-47D3A572-D36D-44C2-860F-4A7470B6670AQ38875552-6536677F-907C-45E3-9B2B-F0EAECF5F545Q39128975-BB4BD393-8CD3-4A9B-8BCE-506FFA6D9950Q39182893-856F6B3D-8DFA-4ACE-A9CB-5DCB73819ADDQ39348454-D577ACE2-AB9B-469D-9B8E-37FC9B2EE55BQ39440714-ECC6F3D2-068E-49B0-837C-A6ADE1E3B420Q39809313-833F045E-EDA3-44C7-BE1C-D899821C92A9Q39914795-3EF8795A-4D3E-42F9-9E40-E3BD3FDF2B65Q39918855-230F0BD0-4BCD-4BAD-876A-2A807B95E46BQ40055337-D38F219D-75A6-4014-9587-0F6964571B89Q40057893-7555C7BE-D655-4DD1-9C90-C8EE510851D4Q41298456-14F60B19-B829-41FB-89BD-8BCEB97F32C7Q42151444-86D3C839-BD35-4BA5-81D3-5DCA72B6A144Q42362761-23127288-13BD-4393-9BF6-6BCC1CDA79EAQ42813475-05762213-868F-4ACF-BC6C-4ECB76097DAFQ45306974-8A8441A2-D8F4-4820-B241-EE60A079DC46Q45916499-A4DDA8A4-3E1E-4ECA-8F5F-3B92A3195A03Q47177430-F86FC529-7B3F-4B07-AD63-1EC87AE940C8
P2860
Aberrant expression of E-cadherin and beta-catenin in human prostate cancer.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Aberrant expression of E-cadherin and beta-catenin in human prostate cancer.
@en
Aberrant expression of E-cadherin and beta-catenin in human prostate cancer.
@nl
type
label
Aberrant expression of E-cadherin and beta-catenin in human prostate cancer.
@en
Aberrant expression of E-cadherin and beta-catenin in human prostate cancer.
@nl
prefLabel
Aberrant expression of E-cadherin and beta-catenin in human prostate cancer.
@en
Aberrant expression of E-cadherin and beta-catenin in human prostate cancer.
@nl
P2093
P1433
P1476
Aberrant expression of E-cadherin and beta-catenin in human prostate cancer.
@en
P2093
Anton Galich
John J Baker
K C Balaji
Lynette M Smith
Meena Jaggi
Sonny L Johansson
P304
P356
10.1016/J.UROLONC.2005.03.024
P577
2005-11-01T00:00:00Z